Ohio University ranks first among Ohio higher education institutions for research licensing revenue, with faculty inventions generating $10.6 million during fiscal year 2014, according to a report from The Association of University Technology Managers (AUTM).
An examination of AUTM data also shows that Ohio University ranks 9 th nationally for research return on investment, which is the amount of research licensing revenue received compared to total institution research and sponsored program funding. Ohio University reported $60.8 million in research and sponsored program funding for fiscal year 2014. National leaders on research return on investment include Auburn University, Northwestern University, Princeton University and New York University.
Most of the Ohio University revenue stems from a license to the Pfizer corporation for a growth hormone receptor antagonist discovered by Edison Biotechnology Institute scientist John Kopchick and former graduate student Wen Chen in 1987. The technology has been developed into a drug marketed by the pharmaceutical company as SOMAVERT® (pegvisomant for injection). SOMAVERT® is a therapeutic for patients with acromegaly, a form of gigantism that leads to medical complications and premature death in adults.
Ohio University has reinvested the licensing revenue in faculty research programs and technology commercialization efforts.
“The university’s successful licensing record has allowed us to enhance our innovation ecosystem,” said Joseph Shields, vice president for research and creative activity and dean of the Graduate College at Ohio University. “We’re proud that our efforts to stimulate faculty research and transfer inventions and technologies to the marketplace are benefitting the general public.”
Contact: Andrea Gibson, director of research communications, (740) 597-2166, email@example.com.